Abstract: The invention concerns stable aqueous solutions containing one or several nucleoside triphosphates wherein the respective solution has a pH value of more than 7.5 and contains no additional substances with a stabilizing effect. The nucleoside triphosphate solutions are used in particular for DNA synthesizing reactions such as e.g. RT-PCR, cycle sequencing, random priming and nick translation. One of the most important applications of such solutions containing deoxy-nucleoside triphosphates (d-NTP) is their use in the polymerase chain reaction (PCR).

Abstract: The invention is directed to compounds of formula (I) wherein R1 alkyl, alkenyl or alkynyl having from 6 to 24 carbon atoms; n=0-12; X=oxygen or NH; and the physiologically safe salts, esters, optically active forms, racemates and derivatives thereof which can be metabolized in vivo to yield compounds of general formula (I), methods of preparing same, and drugs containing said compounds, for treating bone metabolic disorders.

Abstract: The present invention concerns new fluorescent dye systems especially for fluorescence resonance energy transfer determinations for example combined with the time-resolved measurement of the resulting fluorescence. The invention also concerns the use of these dyes to label biomolecules and for the homogeneous determination of interactions between biomolecules, for example for detecting an analyte.

Abstract: The invention concerns a process for coating a metallic or semimetallic surface in which coating molecules containing reactive groups are bound covalently to the surface by irradiation with light and it also concerns a structured coated surface.

Abstract: The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the administration form consisting of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.

Abstract: Test element analysis system (1) for the analytical investigation of a sample (8), in particular of a body liquid, of human beings or of animals, comprising test elements (3) with a test zone (7), to be brought in contact with the sample to be investigated for the purpose of performing an analysis, in order to measure a measurement quantity characteristic for the analysis, and an evaluation instrument (2) with a test element holder (5) for positioning a test element (3) in a measuring position in order to perform a measurement, and a measurement and evaluation electronics (15) for measuring the characteristic change and for determining a result of the analysis, based on the result of the measurement. In order to provide increased measuring accuracy by improved temperature compensation, it is proposed, in the scope of the invention, that the evaluation instrument (2) for the determination of the temperature prevailing in the test zone (7) of the test element (3) comprises an infrared detector (20).

Abstract: The present invention relates to thermostable mutants of B-type DNA polymerases comprising a Y-GG/A amino acid motif between the N-terminal 3?-5?-exonuclease domain and the C-terminal polymerase domain whereas the tyrosine of the Y-GG/A amino acid motif is mutated and whereas these mutant DNA polymerases are suitable for PCR.

Abstract: The invention concerns an analytical device containing at least two components in which at least two of the components are joined together with the aid of an adhesive, which is characterized in that the adhesive contains an adsorptive material. The invention additionally concerns the use of adhesives which contain adsorptive material to manufacture analytical devices.

Abstract: The invention concerns compounds of the general formula (I) in which the residues R1 to R7 have the meanings given in the application as well as methods for their preparation.

Abstract: Magnetic particles are prepared containing a magnetic core coated with a glass layer having a substantially pore-free class surface or having pores with a diameter offices than 10 nm. The particles are used for separating biological material such as nucleic acids. A preferred process of preparing the particles is by forming a mixture of magnetic cores with a sol formed from an alcohol and a metal alkoxide, spray-drying the mixture to coat the cores with a layer of gelled sol, and heating the coated cores to obtain the magnetic glass particles. Preferably, the particles have an average particle size of less than 100 ?m. The magnetic core may be a composite material containing a mica core and magnetite particles immobilized on the mica core, and the glass layer may contain boron oxide. Magnetic core materials include magnetite (Fe3O4) and Fe2O3.

Abstract: The invention relates to a process for the preparation of fast-dissolving pharmaceutical preparations from difficultly soluble active substances, wherein an aqueous suspension is made from the active substance and one or more water-soluble adjuvants and then the resulting aqueous suspension is processed, with removal of the water, by methods conventional per se, to form solid pharmaceutical preparations. The invention also relates to fast-dissolving pharmaceutical preparations of active substances having a dissolution rate of at least 70% after 30 minutes, prepared in accordance with the process of the invention.

Abstract: The invention concerns a method and an arrangement for determining the concentration of glucose in a body fluid. In the microdialysis technology used for this purpose, perfusate containing glucose is transported in intermittent delivery pulses through a microdialysis probe (10) inserted into the body fluid and dialysate obtained in this process is passed to a measuring cell (16) to record the glucose content. In order to achieve an exact determination of glucose even with a reduced dialysis period, it is proposed that the starting content of glucose in the perfusate is adapted to the glucose content of the body fluid by means of a control device (18, 20) in accordance with a command variable derived from the measurement signals of the measuring cell (16). When the control deviation is negligible the momentary starting content of glucose in the perfusate can be determined as a measure for the glucose content of the body fluid.

Abstract: A thermostable enzyme is provided which is derived from the microorganism Anaerocellum thermophilum. The enzyme has a molecular weight of 96 to 100 kDa, shows DNA polymerase activity and reverse transcriptase activity in the presence of magnesium ions. The enzyme may be native or recombinant, and may be used with selected primers and nucleoside triphosphates in a temperature cycling polymerase chain reaction on DNA or RNA as template with or without additional DNA polymerases as an enzyme mixture.

Abstract: A process for selecting human cells for the production of human proteins by endogenous gene activation allows human proteins to be produced in economically feasible quantities and in a form suitable for producing a pharmaceutical composition. Also disclosed is a process for producing human proteins in a cell line identified in this matter.

Abstract: A composition which contains stabilized conjugates composed of colloidal particles and biomolecules is obtained by adding a detergent to a solution containing biomolecules before or/and during treatment of colloidal particles with this solution.

Abstract: Method for sequencing a nucleic acid molecule in a thermocycling reaction which initially comprises a nucleic acid molecule, a first primer, a second primer, a reaction buffer, a first thermostable DNA polymerase, (optionally) a thermostable pyrophosphatase, deoxynucleotides or derivatives thereof and a dideoxynucleotide or a derivative thereof and which is characterized in that the thermocycling reaction additionally contains a second thermostable DNA polymerase which, in comparison to the said first thermostable DNA polymerase, has a reduced ability to incorporate dideoxynucleotides as well as the use of the said method.

Abstract: A solid phase with at least one test area is described which contains reagents for the detection of at least one analyte in a sample, wherein the solid phase additionally comprises at least one control area for the detection of interfering reactions.

Abstract: Process for the production of a protein with citrate lyase activity by expressing a suitable plasmid in a host organism and isolating the protein in an active form, wherein the plasmid contains the information from a gene cluster composed of at least six genes and an inducible promoter. Furthermore the invention concerns the use of the recombinant enzyme and a corresponding test kit for the determination of citric acid.

Abstract: The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.

Abstract: A method is described for the direct, exponential amplification and sequencing (“DEXAS”) of a DNA molecule from a complex mixture of nucleic acids, wherein truncated DNA molecules as well as DNA molecules of full length are synthesized simultaneously and exponentially between two positions on the said DNA molecule, which initially contains a DNA molecule in a thermocycling reaction, a first primer, a second primer, a reaction buffer, a thermostable DNA polymerase, a thermostable pyrophosphatase (optionally), deoxynucleotides or derivatives thereof and a dideoxynucleotide or derivatives thereof.